logo
Carers Week: 'Shining the light' on young carers in South East

Carers Week: 'Shining the light' on young carers in South East

BBC Newsa day ago

For many young people across the South East, their focus revolves around school, homework, catching up with friends and enjoying interests and hobbies.However, some face the extra responsibility of caring for a family member who has a health condition or living with a disability.Billy, 14, from Gravesend in Kent, looks after his older brother Henry, who has autism, ADHD, learning difficulties and a sleeping and eating disorder.His mother Natalie told the BBC: "I feel guilty sometimes because Billy doesn't have a child's life. He doesn't go out with his friends because he wants to stay home and help me."
Billy was eight years old when he started looking after Henry. He said initially he found the extra responsibilities "tough"."I struggled to keep up with homework as well, but I can now manage the different tasks," he added."When I come home from school, I look after Henry. I cook his food, do the washing and I wait for mum as she returns late from work." On Saturdays, Billy tidies the rooms, maintains the front and back gardens and does the shopping.Natalie, who is a single parent, said: "I don't ask Billy to do the tasks, he takes them on himself."
Billy was a recipient of the Community Hero Award at the Gravesham Civic and Community Awards 2025 in May. He is also a member of the Shadow Youth Board and the Young Carer National Voice and he advocates passionately for more support and recognition of young carers.Even though Billy has taken on care responsibilities, he finds time to engage in his own hobbies such as growing tomatoes and playing rugby and basketball. "When I grow up, I want to be a PE teacher or a police officer," he said.
Fifteen-year-old Oliver from Eastbourne in East Sussex is the sole carer for his mother Wendy, who has a pacemaker and a mechanical heart valve and takes special medication for her condition.Oliver was a recipient of BBC's Make A Difference Award last year. While he was recognised for his dedication, he admitted the extra responsibilities are "challenging" at times. "Mum is proud of me. We get through it together and we support each other," Oliver said. Oliver was eight years old when he saved his mother's life by contacting 999 after she collapsed in the middle of the night. He told Radio Sussex that at the time he was dealing with the situation, fear had not crossed his mind."Looking back it was scary," he said. "Mum does feel guilty some times with me looking after her, but I try to let her care for me when she can."
'Young carers feel lonely'
Rosie Lowman, service manager for East Sussex charity Care for the Carers, said it has received an increasing number of referrals for young carers from ages five to 17. According to the charity, there are about 8,000 young carers in the county. To support the youngsters, it has launched a fundraising appeal to keep its Young Carers Groups running.According to Action For Children, eight out of 10 young carers feel lonely during summer holidays. "While many young people look forward to a summer break young carers could face an increase in their caring role and as a result they feel more isolated from their peers," Ms Lowman said."We want to use Carers Week (9-15 June) to shine the light on young carers and how important respite is for them."Oliver said support groups are vital so young carers "do not feel alone". "It's crucial every young carer gets the same opportunities as other young people," Oliver added.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NHS England to roll out pioneering cancer treatment in world first
NHS England to roll out pioneering cancer treatment in world first

The Independent

time34 minutes ago

  • The Independent

NHS England to roll out pioneering cancer treatment in world first

NHS England will be the first health system worldwide to roll out the pioneering "Trojan horse" treatment, belantamab mafodotin (Blenrep), for blood cancer patients. The targeted therapy has shown promising results in halting the progression of myeloma for nearly three times as long as current treatments, benefitting approximately 1,500 patients annually. Blenrep, manufactured by GlaxoSmithKline, has been approved by the National Institute for Health and Care Excellence (Nice) for use within the NHS. It will be available to patients whose cancer has advanced or has not responded to initial treatments. Trials suggest that the treatment, in combination with other drugs, delayed disease progression by an average of three years, compared to just over a year for patients taking commonly used drugs.

NHS patients to receive drug that destroys cancer from inside
NHS patients to receive drug that destroys cancer from inside

Telegraph

timean hour ago

  • Telegraph

NHS patients to receive drug that destroys cancer from inside

A so-called 'Trojan Horse' drug that destroys blood cancer from within is set to be rolled out to thousands of NHS patients. The health service will be the first in the world to make the drug available to patients with multiple myeloma – an incurable cancer of the bone marrow. The drug, called belantamab mafadotin, was developed in the UK and has been dubbed a 'Trojan Horse' therapy because it tricks cancer cells into absorbing it before killing them from within. While the cancer is incurable, treatment is designed to extend people's lives by as much as possible while minimising the impact of side effects and on quality of life. In trials, cancer progression was delayed by three years on average in those taking the drug, which was three times longer than the most common treatment. Around 1,500 patients a year in England will benefit after the treatment was approved by the National Institute for Health and Care Excellence on Thursday. The drug will be offered to patients whose cancer has progressed or not responded to the first choice of treatment using another drug, lenalidomide. Patients who are prescribed the drug will receive it via an infusion once every three weeks in combination with two other cancer treatments.

Blood cancer patients in England first in world to be offered ‘Trojan horse' drug
Blood cancer patients in England first in world to be offered ‘Trojan horse' drug

The Guardian

timean hour ago

  • The Guardian

Blood cancer patients in England first in world to be offered ‘Trojan horse' drug

Thousands of patients in England with blood cancer will become the first in the world to be offered a pioneering 'Trojan horse' drug that sneaks inside cancer cells and wipes them out. In guidance published on Friday, the National Institute for Health and Care Excellence (Nice) gave the green light to belantamab mafodotin, which can halt the advance of multiple myeloma for three times as long as standard treatments. The targeted therapy, which is given as an infusion every three weeks with other cancer drugs, is a special type of antibody drug that targets and attaches to cancer cells. It has been described as a Trojan horse treatment because it works by being taken into a cancer cell and unleashing a high concentration of a lethal molecule to destroy the cell from inside. Prof Peter Johnson, NHS England's national clinical director for cancer, said the drug would be life-changing for patients and their families. 'Myeloma is an aggressive type of blood cancer, but we have seen a steady improvement in the outlook for patients over recent years as we have introduced new targeted therapies,' he said. 'I am delighted that patients in England will be the first to benefit from this new treatment, which has the potential to keep cancer at bay for years longer, giving people the chance of more precious time with friends and family.' About 1,500 patients a year in England with multiple myeloma, an incurable cancer of the bone marrow, will benefit from the treatment, also known as Blenrep and made by GlaxoSmithKline. Health officials said the drug would be offered to patients whose cancer had progressed or failed to respond to another first-line treatment. Shelagh McKinlay, the director of research and advocacy at the blood cancer charity Myeloma UK, said it was fantastic to see the NHS become the first healthcare system in the world to roll out the drug. 'We have been working very hard for the last year to get this treatment approved and we know it will transform the lives of thousands of people with myeloma,' she said. Paul Silvester, 60, from Sheffield, described the impact of the drug as amazing after he was diagnosed with myeloma in 2023. After the first treatment he received failed to stop his cancer progressing, he was given belantamab mafodotin through an early access programme at the Royal Hallamshire hospital. 'I feel like this treatment has brought the party balloons back in the house. It has been amazing – within the first two or three weeks, after the first dose, I was in remission,' he said. Trials suggest the treatment, in combination with bortezomib and dexamethasone, delays progression of the disease by an average of three years, compared with one year for patients taking the commonly used drug daratumumab along with the other treatments. Helen Knight, the director of medicines evaluation at Nice, said: 'This recommendation demonstrates our commitment to getting the best care to patients fast, while ensuring value for the taxpayer.' The health minister Karin Smyth said: 'This groundbreaking therapy puts the NHS at the forefront of cancer innovation. By harnessing cutting-edge 'Trojan horse' technology, we're offering new hope to blood cancer patients across the country.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store